These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 35123662)
1. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Lancet Oncol; 2022 Mar; 23(3):382-392. PubMed ID: 35123662 [TBL] [Abstract][Full Text] [Related]
2. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Lancet; 2015 Oct; 386(10001):1341-1352. PubMed ID: 26211827 [TBL] [Abstract][Full Text] [Related]
3. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer. Bui KT; Willson ML; Goel S; Beith J; Goodwin A Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074 [TBL] [Abstract][Full Text] [Related]
4. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Goel S; Sharma R; Hamilton A; Beith J Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328 [TBL] [Abstract][Full Text] [Related]
5. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Sharma R; Hamilton A; Beith J Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661 [TBL] [Abstract][Full Text] [Related]
6. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Lancet; 2005 May 14-20; 365(9472):1687-717. PubMed ID: 15894097 [TBL] [Abstract][Full Text] [Related]
7. Hormonal therapies for early breast cancer: systematic review and economic evaluation. Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808 [TBL] [Abstract][Full Text] [Related]
8. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. ; Davies C; Godwin J; Gray R; Clarke M; Cutter D; Darby S; McGale P; Pan HC; Taylor C; Wang YC; Dowsett M; Ingle J; Peto R Lancet; 2011 Aug; 378(9793):771-84. PubMed ID: 21802721 [TBL] [Abstract][Full Text] [Related]
9. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Forbes JF; Sestak I; Howell A; Bonanni B; Bundred N; Levy C; von Minckwitz G; Eiermann W; Neven P; Stierer M; Holcombe C; Coleman RE; Jones L; Ellis I; Cuzick J; Lancet; 2016 Feb; 387(10021):866-73. PubMed ID: 26686313 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F; Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983 [TBL] [Abstract][Full Text] [Related]
12. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. Francis PA; Pagani O; Fleming GF; Walley BA; Colleoni M; Láng I; Gómez HL; Tondini C; Ciruelos E; Burstein HJ; Bonnefoi HR; Bellet M; Martino S; Geyer CE; Goetz MP; Stearns V; Pinotti G; Puglisi F; Spazzapan S; Climent MA; Pavesi L; Ruhstaller T; Davidson NE; Coleman R; Debled M; Buchholz S; Ingle JN; Winer EP; Maibach R; Rabaglio-Poretti M; Ruepp B; Di Leo A; Coates AS; Gelber RD; Goldhirsch A; Regan MM; N Engl J Med; 2018 Jul; 379(2):122-137. PubMed ID: 29863451 [TBL] [Abstract][Full Text] [Related]
13. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Davies C; Pan H; Godwin J; Gray R; Arriagada R; Raina V; Abraham M; Medeiros Alencar VH; Badran A; Bonfill X; Bradbury J; Clarke M; Collins R; Davis SR; Delmestri A; Forbes JF; Haddad P; Hou MF; Inbar M; Khaled H; Kielanowska J; Kwan WH; Mathew BS; Mittra I; Müller B; Nicolucci A; Peralta O; Pernas F; Petruzelka L; Pienkowski T; Radhika R; Rajan B; Rubach MT; Tort S; Urrútia G; Valentini M; Wang Y; Peto R; Lancet; 2013 Mar; 381(9869):805-16. PubMed ID: 23219286 [TBL] [Abstract][Full Text] [Related]
14. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. Jakesz R; Greil R; Gnant M; Schmid M; Kwasny W; Kubista E; Mlineritsch B; Tausch C; Stierer M; Hofbauer F; Renner K; Dadak C; Rücklinger E; Samonigg H; J Natl Cancer Inst; 2007 Dec; 99(24):1845-53. PubMed ID: 18073378 [TBL] [Abstract][Full Text] [Related]
15. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801 [TBL] [Abstract][Full Text] [Related]
16. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women. Jahanzeb M Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537 [TBL] [Abstract][Full Text] [Related]
17. Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer. O'Regan RM; Zhang Y; Fleming GF; Francis PA; Kammler R; Viale G; Dell'Orto P; Lang I; Bellet M; Bonnefoi HR; Tondini C; Villa F; Bernardo A; Ciruelos EM; Neven P; Karlsson P; Müller B; Jochum W; Zaman K; Martino S; Geyer CE; Jerzak KJ; Davidson NE; Coleman RE; Ingle JN; van Mackelenbergh MT; Loi S; Colleoni M; Schnabel CA; Treuner K; Regan MM JAMA Oncol; 2024 Oct; 10(10):1379-1389. PubMed ID: 39145953 [TBL] [Abstract][Full Text] [Related]
18. Effects of adjuvant tamoxifen over three decades on breast cancer-free and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer randomised in the Swedish SBII:2pre trial. Ekholm M; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Rydén L; Eur J Cancer; 2019 Mar; 110():53-61. PubMed ID: 30769227 [TBL] [Abstract][Full Text] [Related]
19. Tamoxifen for early breast cancer. Early Breast Cancer Trialists' Collaborative Group Cochrane Database Syst Rev; 2001; (1):CD000486. PubMed ID: 11279694 [TBL] [Abstract][Full Text] [Related]
20. WITHDRAWN: Tamoxifen for early breast cancer. Clarke MJ Cochrane Database Syst Rev; 2008 Oct; 2008(4):CD000486. PubMed ID: 18843611 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]